Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease.

Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease. Ren Fail. 2018 Nov;40(1):92-98 Authors: Montes-Rivera JO, Tamay-Cach F, Quintana-Pérez JC, Guevara-Salazar JA, Trujillo-Ferrara JG, Del Valle-Mondragón L, Arellano-Mendoza MG Abstract A worldwide public health problem is chronic kidney disease (CKD) presenting alarming epidemiological data. It currently affects about 10% of the adult population worldwide and has a high mortality rate. It is now known that oxidative stress represents one of the most important mechanisms in its pathophysiology, from the early stages to the terminal phase. Oxidation increases inflammation and reduces the capacity of NO• to relax vascular smooth muscle, in part by decreasing bioavailability of tetrahydrobiopterin (BH4), leading to endothelial dysfunction and high blood pressure, and due to the limited effectiveness of existing treatments, new drugs are needed to prevent and/or treat these mechanisms. The aim of this study was to test apocynin in a 5/6 nephrectomy mouse model of CKD to investigate whether its known antioxidant effect can improve the disease outcome. This effect results from the inhibition of NADPH oxidase and consequently a reduced production of the superoxide anion ([Formula: see text]). Animals were divided into five groups: sham, 5/6 nephrectomy only, and 5/6 nephrectomy followed by treatment with captopril, losartan or ...
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research